Xenon Pharmaceuticals: Azetukalner Nears Late-Stage Development in Neurological Therapeutics
We at Xenon Pharmaceuticals focus on new treatments for brain disorders. Our main drug, azetukalner, opens certain channels in the brain. It targets epilepsy and depression.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →